Compare Lattice Semiconductor Corporation Common Stock (LSCC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Lattice Semiconductor (LSCC) trades at $121.15, down 1.38% today, with a bullish technical signal from moving averages. The company shows strong revenue growth projections from $523M in 2025 to $651M in 2026, though current valuation metrics remain elevated with a P/E of 504.2. Recent news highlights leadership in AI infrastructure security and new FPGA product launches, supported by overwhelmingly positive analyst sentiment with 88% buy ratings.

LSCC presents growth potential through AI-driven semiconductor demand and expanding product portfolio, but faces risks from high valuations and competitive pressures. The consensus price target of $162.14 suggests 34% upside, though investors should monitor execution on projected margin expansion from 0.58% to 5.57% net profit margin.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.